Milan, Italy – Dipharma Francis S.r.l is proud to announce that our Caronno Pertusella manufacturing site (Italy) has successfully renewed its CBPF certification, in addition to those from the FDA and the Italian Ministry of Health (AIFA).
Granted by ANVISA (Agência Nacional de Vigilância Sanitária), the Certificado de Boas Práticas de Fabricação de Insumos Farmacêuticos confirms our continued compliance with Brazilian GMP standards.
This achievement follows the certification of our Baranzate (MI) site, which has been approved by ANVISA since 2022 and renewed on November 2024, further strengthening Dipharma’s commitment to quality and regulatory excellence across all our facilities.
The renewal reflects our enduring dedication to excellence, ensuring that our customers worldwide can rely on Dipharma for compliant and high-quality API manufacturing.
For more information:
Paola Clerici
Communication Manager
Dipharma Francis S.r.l.
E-mail: paola.clerici@dipharma.com
